76results about "Antivirals" patented technology

The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The recombinant human interferon modified by polyethylene glycol is characterized by that on the recombinant human interferon one or two or more than two polyethylene glycol chains can be connected, said recombinant human interferon can be interferon alpha 2b, and the average degree of polymerization of said polyethylene glycol chain is 45-230. Said invented recombinant human interferon has the physiological activity of the interferon, and its stability is superior to that of interferon, its plasma clearance is low, the half-life period in vivo is long, it can be used for preparing the medicines for resisting virus and resisting cancer. Said invention also discloses its preparation method.

The invention provides a traditional Chinese medicine microbial ecological agent for preventing and treating infectious bursal disease of chicken and a preparation method thereof. The preparation method comprises the following steps: adding water to radix isatidis, honeysuckle, forsythia, folium isatidis, humulus scandens, radix scutellariae, dangshen, ageratum, plantain, astragalus membranaceus, angelica sinensis and liquorice, boiling by using high heat, preserving heat for 30-60 minutes by using slow fire, cooling, filtering, collecting filtrate, adding white sugar, boiling, cooling to a normal temperature, then inoculating lactobacillus, zygosaccharomyces bailii and acetobacter xylinum, and fermenting for 3-7 days so as to obtain the microbial ecological agent. After the microbial ecological agent is diluted proportionally, the diluted microbial ecological agent is directly drunk by chicken. The traditional Chinese medicine microbial ecological agent provided by the invention has the effects of resisting viruses, inducing interferon, increasing the quantity of effective microbial communities in intestinal tracts, boosting immunity and improving disease resistance of chickens without toxic or side effects and the like; the preparation method is simple, convenient to use and high in viable bacteria content and has no residues. The traditional Chinese medicine microbial ecological agent provided by the invention has a certain curative effect on infectious bronchitis and henpox and relatively good market prospect.

The invention discloses an O type foot and mouth disease virus-like particle vaccine as well as a preparation method and an application thereof, and belongs to the fields of genetic engineering and immunology, aiming at solving the problems of an existing inactivated foot and mouth disease vaccine which is poor in safety and unsatisfying in use effect. The amino acid sequence of the vaccine is shown as SEQ ID NO: 1 in a sequence list, and a nucleotide sequence for encoding the amino acid sequence is shown as SEQ ID NO: 2 in the sequence list. After being immunized, the vaccine can induce an animal to simultaneously generate an O type foot and mouth disease resistant antibody; the vaccine exists in the form of virus-like particles, and foot and mouth disease virus VP1 epitope locates on the surface of the virus-like particles. According to the invention, the amino acid sequence constituting the virus-like particle vaccine and the nucleotide sequence for encoding the amino acid sequence are provided, and the nucleotide sequence contains all genes of coat protein which can be self-assembled as the virus-like particles in expression. The preparation of the O type foot and mouth disease virus-like particle vaccine disclosed by the invention is good in safety and free from the probability of reversion or toxin dispersion; and the vaccine is long in immunizing validity period and convenient in transportation and storage.

Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5′ to 3′ orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.

A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS.

The invention discloses an immunopotentiator and a vaccine preparation for emergency vaccination of Newcastle disease. The active ingredient of the immunopotentiator is composed of sword bean hemagglutinin, panaxoside and astragalus polysaccharide; the vaccine preparation for emergency vaccination of Newcastle disease is composed of the immunopotentiator and Newcastle disease inactivated vaccine according to a volume ratio of 1: (5-25). After being emergently inoculated to chicken, the vaccine preparation disclosed by the invention can be used for effectively controlling the development of epidemic situation and replacing emergently inoculated virulent or attenuated vaccine, the attenuated vaccine not only brings poison and has the possibility of strong virulence return; on the other hand, the vaccine preparation can be used for compensating the defects of slow generation of antibody of the inactivated vaccine to unfavorably control the epidemic situation; meanwhile, the active ingredient of the immunopotentiator is composed of sword bean hemagglutinin, panaxoside and astragalus polysaccharide, and these extracts are active components extracted from plants, thereby meeting the requirements of environmental protection, moreover, the method is simple to operate, capable of quickly generating protective antibody, safe and effective, thereby having promotion significance.

The invention discloses a preparation method of a ganciclovir powder injection and a filter press used by the same, and belongs to the technical field of medicine production. The preparation method includes refining crude ganciclovir twice, evenly mixing the refined ganciclovir with a filtered glycerin sodium chloride aqueous solution and finally freeze-drying the mixture to obtain the ganciclovirpowder injection. The filter press comprises a bracket, a thrust plate, a press plate, a filter plate, a filter cloth and a driving component, and the filter cloth and the filter plate are separatedand installed on a frame body made of polypropylene. The upper and lower edges of the frame body are respectively provided with a deep clamping groove and a shallow clamping groove corresponding to anupper guide rod and a lower guide rod, installation and removal can be performed on the upper guide rod and the lower guide rod conveniently, a first sealing assembly is respectively arranged on thefilter plates on two sides of the frame body, and a second sealing assembly is respectively arranged on the opposite sides of the two adjacent filter plates. The ganciclovir powder injection has relatively less impurity content, and can improve the effect of the ganciclovir powder injection. The filter press facilitates collection of a filtrate and a filter cake and cleaning and replacement of thefilter cloth.

The invention discloses formamide and isonitrile compounds serving as influenza A virus inhibitors and preparation and application thereof. The structural formulae of the formamide-isonitrile compounds serving as the influenza A virus inhibitors are shown as a formula I and a formula II described in the specification, wherein R is selected from alkyl, naphthenic group, aromatic group, heteroaromatics group, amino acid group and substitutive derivatives of all the groups; the substituent groups of the substitutive derivatives are alkyl, naphthenic group, aromatic group, heteroaromatics group and amino acid group. The formamide and isonitrile compounds are prepared from amine serving as a raw material by means of acylation, dehydration and the like. These formamide and isonitrile compounds and pharmaceutically-acceptable salts thereof can be used for preparing anti-influenza medicaments of which the activities are much higher than that of an existing anti-influenza medicament, namely, amantadine, and the drug tolerance generated by existing compounds can be overcome.

The invention belongs to the field of biological medicine, and relates to a long-acting HIV fusion inhibitor for treating acquired immune deficiency syndrome and application thereof. The long-acting HIV fusion inhibitor comprises a polypeptide part for inhibiting HIV membrane fusion and a part capable of being specifically combined with human immune globulin Fc, it is proved through experiments that the half-life period of the long-acting HIV fusion inhibitor in a rhesus monkey is about 11 times that of the HIV fusion inhibitor T20 which is first approved for marketing and has excellent antiviral activity to HIV-1IIIB and HIV-1Bal, the IC50 values are about 5.9 nM and 2.57 nM respectively, the antiviral activity is about 3 times that of T20, and the long-acting HIV fusion inhibitor has low toxicity to cells. The long-acting HIV fusion inhibitor IBP-CP24 polypeptide can be used for preparing a drug for resisting human immunodeficiency viruses for a long time and providing a new strategy for prolonging the half-life period of protein and polypeptide drugs in the body.

The invention discloses the use of human interleukin 32 in the preparation of medicaments for treating or preventing influenza A virus infection. Clones of splicing isoforms IL-32(alpha, beta, gamma, delta, epsilon and zeta) of IL-32 are cloned and established by using a molecular biological method; MDCK cells are transfected with the clones; and thus, the applicant has found that MDCK cells in which all subtypes of the human interleukin 32 are overexpressed are improved in resistance to influenza A viruses. Different IL-32 subtypes show different inhibition effects on the replication of the influenza A viruses. The IL-32 gamma has the most obvious anti-influenza A virus effect. And only the IL-32 gamma is of a secretor type. The human interleukin 32 is a critical antiviral gene in immunoreactions of a host. The applicant is the first one to put forward that the human interleukin 32 has an extremely effective anti-influenza A virus function and to point out that the human interleukin 32 has an application prospect in developing anti-influenza A virus medicaments for effectively preventing and treating influenza A virus infection.

The invention discloses a preparation method of high-purity gynostemma pentaphylla total saponin for veterinary drugs. The preparation method is characterized in that a medicinal gynostemma pentaphylla total saponin medicinal material is used as a raw material, and the high-purity target product, namely the gynostemma pentaphylla total saponin for the veterinary drug, is obtained by high-efficiency extraction and separation on the basis of combination of technologies such as continuous countercurrent supersonic wave extraction, ceramic membrane microfiltration and macroporous resin adsorption separation with a conventional solvent reflux extraction principle. The preparation method has the advantages that the product purity and the product yield are improved, the product quality and the high quality are stabilized, the production cost is reduced, the requirements on the development of the high-purity gynostemma pentaphylla total saponin for the veterinary drugs and highly-processed products of gynostemma pentaphylla total saponin are satisfied, the production process is in line with environmental protection requirements, and the difficulty in the coordination of working procedures such as extraction, solvent recovery, enrichment and purification occurring in the volume production process of the gynostemma pentaphylla total saponin for the veterinary drugs is solved through the continuous improvement of the technology and the adjustment of technological processes and technical parameters.

The invention relates to the technical field of biomedical engineering and discloses a production method of fusion protein (F-Fc) of RSV (respiratory syncytial virus) antigen protein F and antibody constant region Fc, and application of the fusion protein as RSV subunit vaccine. The method includes: establishing a eukaryotic expression vector of the fusion protein containing RSV protein F and human IgG2Fc by molecular cloning, transfecting CHO (Chinese hamster ovary) cells, and expressing the fusion protein; performing protein A affinity chromatography to obtain high-purity fusion protein; performing fusion protein nasal dripping to immunize BABL/c mice to trigger specific mucosal immunity against the RSV, humoral immunity and 'Th1/Th2 balanced' cellular immunity partial to Th1 type, and thereby effectively inhibiting RSV infections.

The present invention relates to an siRNA (small interfering RNA) having antiviral activity against nonpolio enteroviruses, and a pharmaceutical composition comprising same as an active ingredient for preventing and treating diseases caused by nonpolio enterovirus infection.

The invention relates to the technical field of genetic engineering of recombinant viruses, in particular to an application and preparation method of a candidate strain of a human type-3 adenovirus expressed human type-14 adenovirus neutralization epitope vaccine. Two human type-14 adenovirus neutralization epitopes are respectively embedded to hexons of human type-3 adenoviruses to be displayed on the surfaces of the hexons. The candidate strain of the vaccine is capable of inducing strong anti-HAdv14 and anti-HAdv3 infection immunoreactions and can be used for preparation of bivalent vaccines for prevention of HAdv14 and HAdv3 infection.

The invention provides compositions of oligonucleotides targeted at influenza genes and at host animal genes involved in response to influenza infection. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment and prevention of influenza.

A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-thymine nucleotide, or a phosphate prodrug thereof, optionally in combination therapy with other drugs for the treatment of HBV.

The invention discloses a novel coronavirus (SARS-CoV-2) vaccine antigen presentation system of attenuated salmonella secretory expression NTD structural domain protein and application of the novel coronavirus (SARS-CoV-2) vaccine antigen presentation system. The novel coronavirus (SARS-CoV-2) vaccine antigen presentation system is used for preventing novel coronavirus (SARS-CoV-2). By constructing the controllable and stable expression plasmid for secreting and expressing the NTD structural domain protein and performing engineering modification on the attenuated salmonella, the antigenic protein can be efficiently delivered to an antigen presenting cell by virtue of a specific secretion system of the attenuated salmonella after administration in an oral way. The delivered antigenic protein can be effectively treated and presented by antigen presenting cells, and finally, the immune system is activated/regulated, an antibody is generated, and the effect of a vaccine is achieved.